GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2011

Affymetrix to Pay $330M to acquire eBioscience

  • Affymetrix is buying San Diego-based eBioscience for $330 million in cash. eBioscience is specialized in the field of flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

    Affymetrix says the acquisition will complement its traditional businesses of genomics and cytogenetics, enhance its molecular diagnostics business, and expand its product portfolio to include multicolor flow cytometry reagents and a range of reagents for analyzing cytokines, growth factors, and other soluble proteins. The takeover will in addition boost new product and growth opportunities for its Panomics subsidiary’s RNA and protein analysis business.

    eBiosciences is predicted to generate sales of over $70 million in 2011, with gross margins in excess of 70%, Affymetrix says. “The acquisition of eBioscience is transformational for our business,” comments Frank Witney, Ph.D., president and CEO. “With eBioscience, Affymetrix will significantly expand its addressable markets by adding an industry-leading portfolio of cell-based assays and immunoassays. These new products are a critical part of our customers’ workflow in our key target markets of translational medicine, oncology, and immunology.”  

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »